ProShares UltraShort NASDAQ Biotechnology
11 hedge funds and large institutions have $6.05M invested in ProShares UltraShort NASDAQ Biotechnology in 2018 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
26% more capital invested
Capital invested by funds: $4.82M → $6.05M (+$1.23M)
0.69% more ownership
Funds ownership: 1.49% → 2.18% (+0.69%)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$1M |
| 2 |
WP
WealthSource Partners
San Luis Obispo,
California
|
+$492K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$312K |
| 4 |
Jane Street
New York
|
+$215K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$90.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$931K |
| 2 |
Morgan Stanley
New York
|
-$25K |
| 3 |
CA
Calton & Associates
Tampa,
Florida
|
-$22K |
| 4 |
Citigroup
New York
|
-$9.95K |
BIS Hedge Fund Activity: Q1 2018 in Review
11 of the 4,372 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q1 2018, worth a combined $6.05M — up 26% from $4.82M a quarter earlier.
Fund positioning in BIS was balanced in Q1 2018: 2 funds opened new positions, 2 closed out, 6 added to existing stakes and 2 trimmed.
The largest buyer was Healthcare Value Capital, adding an estimated $1M. The largest seller was Virtu Financial, cutting an estimated $931K.
- 11 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $6.05M of ProShares UltraShort NASDAQ Biotechnology stock for Q1 2018, up 26% quarter-over-quarter.
- 2 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q1 2018 and 2 closed out, a net change of 0 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q1 2018 was Healthcare Value Capital, an estimated $1M added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q1 2018 was Virtu Financial, an estimated $931K sold.
Based on aggregated 13F filings for Q1 2018.